ADAR1 Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

ADAR1 Capital Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.1M	Sell	166,550 -62,349	-27%	-$3.46M	0.46%	54
2026 Q1	$13.3M	Buy	228,899 +24,930	+12%	+$1.15M	0.78%	30
2025 Q4	$9.14M	Buy	203,969 +14,871	+8%	+$625K	0.67%	37
2025 Q3	$7.59M	Sell	189,098 -70,405	-27%	-$2.48M	0.71%	38
2025 Q2	$8.12M	Buy	259,503 +131,955	+103%	+$4.3M	1.25%	20
2025 Q1	$4.28M	Buy	127,548 +77,001	+152%	+$2.92M	0.79%	33
2024 Q4	$1.98M	Buy	50,547 +22,644	+81%	+$936K	0.4%	49
2024 Q3	$1.1M	Buy	27,903 +23,203	+494%	+$936K	0.18%	66
2024 Q2	$183K	Buy	+4,700	New	+$188K	0.03%	146

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ADAR1 Capital Management's XENE Position: Q2 2026 in Review

ADAR1 Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 27% in Q2 2026, selling an estimated $3.46M and leaving 166,550 shares worth $10.1M. The position accounts for 0.46% of the portfolio, ranked #54.

ADAR1 Capital Management first reported a position in XENE in Q2 2024 and has held it in 9 quarters since. The position peaked at $13.3M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

ADAR1 Capital Management held 166,550 shares of Xenon Pharmaceuticals worth $10.1M as of Q2 2026.
ADAR1 Capital Management sold 62,349 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.46M.
Xenon Pharmaceuticals made up 0.46% of ADAR1 Capital Management's portfolio in Q2 2026, its #54 holding.
ADAR1 Capital Management first reported a position in Xenon Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
ADAR1 Capital Management's Xenon Pharmaceuticals position peaked at $13.3M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.